Improving QoL and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
July 13, 2020
Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC, Results from the CARD Study
Karim Fizazi, MD, Ph.D.
In this discussion on the CARD study with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from his presentation at this years ASCO Genitourinary Symposium.
Management of Castration-Resistant Prostate Cancer
Cora Sternberg MD, FACP
Cora Sternberg joins Alicia Morgans and shares highlights from the Management of castration-resistant prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference and key takeaways from the session when thinking about managing these patients with this disease.
The Impact of Treatment Delays on Prostate Cancer During the COVID-19 Pandemic - Zach Klaassen & Chris Wallis
Zachary Klaassen, MD, MSc and Christopher J.D. Wallis, MD, PhD
Christopher Wallis and Zachary Klaassen join Alicia Morgans to discuss the management guidance released by European Urology on how to best optimize the care of prostate cancer patients during the COVID-19 pandemic.
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy
A. Oliver Sartor, MD
The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic
Edward M. Schaeffer, MD, Ph.D.
The National Comprehensive Cancer Network released new guidelines, on April 1, 2020, directing cancer care during the COVID-19 crisis, Alicia Morgans and Edward Schaeffer address patient questions about their primary treatment concerns during this unprecedented time.